NCT05659433View on ClinicalTrials.gov

Contrast-enhanced vs. B-mode Ultrasound-guided Percutaneous Biopsy of Retroperitoneal Tumors

NACompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

September 15, 2022

Study Completion Date

November 30, 2022

Conditions
Retroperitoneal Neoplasms
Interventions
PROCEDURE

CEUS-guided percutaneous biopsy

A standard dose of SonoVue ultrasound contrast agent is injected prior to the biopsy, and the percutaneous biopsy is guided in real time, targeting the contrast-enhanced areas of the retroperitoneal tumors (viable, vascularized)

PROCEDURE

B-mode US-guided percutaneous biopsy

Standard of care (B-mode) ultrasound-guided percutaneous biopsy, without contrast enhancement

Trial Locations (1)

400162

Prof. Dr. O. Fodor Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca

All Listed Sponsors
collaborator

Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor

OTHER

lead

Iuliu Hatieganu University of Medicine and Pharmacy

OTHER

NCT05659433 - Contrast-enhanced vs. B-mode Ultrasound-guided Percutaneous Biopsy of Retroperitoneal Tumors | Biotech Hunter | Biotech Hunter